PharmaTwoBLogo copy.jpg
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
23 avr. 2023 08h30 HE | PHARMA TWO B LTD
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
Longboard Logo.jpg
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
01 avr. 2022 08h30 HE | Longboard Pharmaceuticals, Inc.
Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage...
Biogen_Logo_Standard-rgb_R.jpg
Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
07 mai 2019 07h30 HE | Biogen Inc.
Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI® (natalizumab) in patients in a real-world setting New interim data further...
MDA, AAN and ABF Awa
MDA, AAN and ABF Award Clinical Research Training Fellowship for Muscular Dystrophy
14 juil. 2017 11h04 HE | Muscular Dystrophy Association
Chicago, IL, July 14, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), together with the American Academy of Neurology (AAN) and the American Brain Foundation (ABF), is pleased to...